Remote Detailing in Pharma: Trends, Tech, and Compliance

Remote detailing adoption surged during the COVID-19 pandemic and remains part of many pharmaceutical companies' engagement mix. In BCG's third-quarter 2022 survey of more than 1,200 physicians in China, Germany, Japan, and the United States, 84% of physicians said they preferred to maintain or increase the share of virtual interactions with pharmaceutical companies (^[6]). This historical result should not be presented as a 2025 industry survey or generalized beyond the surveyed markets and respondents.

The trend toward hybrid engagement has stabilized. A Syneos Health study found that in‑person detailing fell from ~89% of interactions before COVID to 0% at the worst point, then recovered to approximately 62% by mid‑2021 (^[7]). By 2024, in-person sales rep engagement had declined further to 56.5% (down from 67.8% in prior years), with marketers continuing to shift budgets toward digital channels (^[8]). A 2019 Veeva guide, citing Ashfield Healthcare, reported that 78% of HCPs said meetings and events should be a mixture of physical and virtual formats; this is a historical finding, not a current measure of HCP preferences (^[9]).

These trends are summarized below:

Metric	Value	Scope and source
Physicians preferring to maintain or increase virtual interaction share	84%	More than 1,200 physicians in China, Germany, Japan, and the United States; BCG, Q3 2022 ([6])

These survey findings support a hybrid engagement model, but they do not establish a universal long-term decline in face-to-face interactions. In BCG's third-quarter 2022 survey, face-to-face interactions between physicians and pharmaceutical-company representatives had returned to prepandemic levels, while virtual channels remained an established part of the engagement mix (^[10]).

From an IT and operational standpoint, remote detailing offers significant advantages but also introduces new challenges:

• Benefits (IT Perspective): Virtual detailing greatly scales rep reach – a single rep can make many more calls per day (no travel) and cover remote or hospital accounts otherwise hard to reach (^[11]). Digital calls are typically longer and more engaging than quick hallway drops: one report found remote calls average ~14 minutes (versus ~2 minutes in person) (^[12]). Platforms automatically capture rich data and analytics on HCP engagement (e.g. which slides were viewed, polls clicked) (^[13]) (^[12]). Content updates and compliance are easier: approved promotional materials can be updated centrally and pushed live to all reps, ensuring consistent messaging (^[14]) (^[15]). Cost savings accrue from reduced travel and printing (^[16]). Remote systems can be integrated with CRM/CLM (e.g. Veeva CRM, Salesforce Health Cloud) so calls are logged automatically with the correct HCP records, feeding into reporting dashboards. Security is also improved in some respects: modern platforms support encryption and access controls, safeguarding proprietary slides and any PHI that might arise (^[17]) (^[18]).

• Challenges: IT teams must invest in reliable infrastructure and devices. Equipping reps with tablets or laptops and high‑speed connections can be expensive (^[19]). Video calls must be rock-solid; dropped calls or poor audio/video degrade HCP trust. Ensuring tools integrate with existing systems is non‑trivial: CRM platforms may require custom APIs or middleware to sync virtual call logs and content usage data. Security and compliance are paramount: platforms must encrypt data in transit and at rest and meet healthcare privacy standards (^[18]) (^[20]). If any patient-specific data enters a discussion (e.g. case studies), HIPAA rules could apply, so IT must enforce strict access controls and audit trails. Finally, users need training on the new tools; poor uptake by reps or HCPs can limit ROI (^[21]) (^[22]). Designing an engaging virtual experience is also harder – the lack of face‑to‑face cues means reps must adapt presentation styles and content (e.g. more interactive polls or infographics) to maintain attention (^[21]).

Benefits vs. Challenges

Benefits	Challenges
Reach more HCPs per day (no travel)	Requires investment in devices, bandwidth ([19])
Rich digital analytics on engagement ([13])	Ensuring reliable video/audio quality (tech reliability) ([21])
Easy content updates & consistency ([14])	Integrating with existing CRMs/CLM systems
Lower cost per call (no printed materials) ([16])	Data security/privacy compliance (HIPAA concerns) ([20]) ([18])
Ability to train/roll out new content centrally ([14])	Needs user training and change management ([23]) ([22])

The life sciences CRM landscape continues to evolve. Pharma companies use a mix of specialized and general-purpose tools for remote engagement, including the following examples:

• Veeva Vault CRM (Engage Meeting): Veeva's pharma‑focused platform with built-in remote detailing capabilities. Sales and medical teams can schedule virtual calls, present approved slides/videos in real time, and capture all interaction data in CRM. Veeva's Engage Meeting feature enables two‑way communication with HCPs, including integrated chat and messaging capabilities (^[24]). The 2025 release (25R1.0) added Microsoft Outlook calendar integration and enhanced sandbox configuration for testing (^[25]). In October 2025, Veeva said AI Agents for commercial applications, including Vault CRM, were planned to be available starting in December 2025 (^[26]).

• IQVIA OCE CRM: In April 2024, IQVIA and Salesforce announced that IQVIA would license OCE CRM-related software to Salesforce and collaborate on Life Sciences Cloud for customer engagement. IQVIA said it would continue to market OCE CRM and support its nearly 400 global OCE customers in more than 130 countries through 2029, with the companies coordinating the transition to Salesforce's next-generation life sciences solution (^[27]).

• Salesforce Agentforce Life Sciences for Customer Engagement: Salesforce announced the availability of Life Sciences Cloud for Customer Engagement on September 25, 2025. In a separate August 2025 announcement, Salesforce said that more than 70 industry-leading customers had selected Life Sciences Cloud, naming Fresenius Kabi, Pfizer, and Takeda. ZS subsequently described Salesforce Agentforce Life Sciences as the former Life Sciences Cloud. The offering includes agent-first features for customer engagement, including Smart Summaries and voice-activated account preparation; Salesforce described additional capabilities, including podcast-style recaps and AI-enabled compliance, as planned features (^[28]) (^[29]) (^[30]).

• Microsoft Teams / Zoom: Many field reps use enterprise video platforms for flexibility. These provide reliable video/audio and screen sharing; IT can deploy enterprise‑licensed versions (e.g. Teams with HIPAA compliance) and integrate with calendars (^[31]).

Table: Remote Detailing Technologies (2025-2026)

Tool/Platform	Category	Key Features/Notes
Veeva Vault CRM (Engage Meeting)	eDetailing/CRM	Cloud-based detailing, live 2-way HCP engagement, integrated chat, and compliance tracking; Veeva said AI Agents for Vault CRM were planned to be available starting in December 2025
IQVIA OCE CRM	CRM	IQVIA said it would continue to market OCE CRM and support existing customers through 2029 while coordinating a transition to Salesforce's next-generation life sciences solution ([27])
Salesforce Agentforce Life Sciences	CRM/eDetailing	Customer Engagement availability announced Sept. 25, 2025; Salesforce said 70+ customers had selected Life Sciences Cloud in a separate August announcement; agent-first features include Smart Summaries and account-preparation capabilities
Microsoft Teams / Zoom	Video conferencing	Enterprise video calls with screen sharing; HIPAA obligations depend on the deployment, safeguards, and applicable business-associate agreements ([32])
AI-Powered Tools (MAPTUAL, etc.)	Next-Best-Action	MAPTUAL describes its product as an AI-driven platform that integrates pharma data to provide real-time insights and a next-best-action workflow ([33])

Implementing remote detailing at scale requires IT rigor. Key practices include:

• Infrastructure Planning: Adopt cloud services (e.g. Azure, AWS) to handle large concurrent video traffic. Use content delivery networks (CDNs) so reps in any region get good performance. Plan for elastic scalability (auto-scaling servers, databases) to handle usage spikes.
• Security and Compliance: Conduct thorough security audits before rollout (^[18]). Enforce least-privilege access: only authorized reps can start calls or present content. Encrypt all call streams and data at rest (^[18]). Use enterprise login (SSO with MFA) for all platforms. Maintain full audit logs of who presented what, in case FDA or internal compliance needs traceability. If any PHI might be discussed, choose HIPAA-compliant video solutions (e.g. Zoom for Healthcare). Regularly patch and update software and apply network segmentation if needed (^[18]).
• Integration and APIs: Leverage open APIs/SDKs of your CRM and video tools to integrate them. For example, use Veeva or Salesforce APIs to log call records and rep‑HCP relationships. Test integrations thoroughly in a staging environment (^[34]) before go-live.
• Testing and Monitoring: Establish a test environment that mirrors production scale; perform automated and stress tests on the video service (^[35]). Monitor call quality and usage in real time (via dashboards or logs) so that IT can detect dropouts or high latency. Prepare incident response plans for outages or security incidents (^[18]) (^[36]).
• User Training and Change Management: Provide comprehensive training for sales reps and support staff (including quick-start guides, mock sessions, video tutorials). Hold change management sessions so reps understand how to adapt their style for video calls. Engage key field leaders early to champion the tools (^[23]).

Adhering to these practices will maximize uptime, user adoption, and data security for remote detailing programs.

• IQVIA – Abiogen Pharma (Italy): In 2020, Abiogen Pharma (mid-sized biotech) rapidly deployed IQVIA's OCE Remote Engagement. Reps took just 1.5 hours average training, and the system was live in one week. Within days, Abiogen's field team conducted 500+ remote calls per day, each ~10–20 minutes long. The calls focused on knowledge transfer and used interactive quizzes, resulting in high HCP satisfaction and adoption by reps. This case highlights how a familiar platform (IQVIA OCE) enabled quick scaling of virtual interactions without disrupting existing CRM workflows.
• Virtual Rep at Large Pharma: According to industry reporting, many top pharma (e.g. Pfizer, Novartis, etc.) have integrated remote detailing into their processes. Veeva notes that by enabling remote eDetailing in their CRM, reps can schedule virtual calls that automatically capture analytics. In practice, analysts found remote calls 2–8× longer on average than brief office visits (^[12]). This deeper engagement can translate to better educational outcomes. (For example, Veeva reports that HCPs retain more information from scheduled video calls than from rushed in-person drop-ins (^[12]).) Moreover, by reducing travel, one rep can cover a geographically wider territory, including clinics in rural areas or hospital settings where in-person visits are restricted (^[37]).
• Technology Adoption Example: Veeva's CRM CoBrowse (2015) was explicitly designed as a cloud remote-detailing tool. It allowed call center or sales teams to "lead HCPs through approved promotional and medical content" online, with a two‑way dialogue (^[38]). All content (videos, PDF, slides) was streamed securely and every interaction detail saved in CRM (^[38]). This illustrates how a purpose-built eDetailing solution can blend content management, regulatory compliance (only approved content used), and multi-channel analytics.

These examples illustrate how remote detailing can be deployed and scaled as part of a hybrid engagement model; they do not establish that it is a safe substitute for face-to-face calls or that educational impact is unchanged.

Remote detailing is subject to the same FDA and privacy regulations as any promotional activity, but 2025 brought significant regulatory developments that pharma companies must navigate carefully.

2025 FDA Enforcement Action: On September 9, 2025, HHS and FDA announced enforcement action concerning misleading DTC prescription-drug advertising and stated that FDA was initiating rulemaking concerning the broadcast-advertising “adequate provision” requirement (^[39]). The announcement should not be read as a new, finalized rule or as establishing requirements specific to every remote HCP interaction.

Remote promotional communications should be reviewed under the requirements that apply to the product and communication. For FDA-regulated promotional communications about prescription reference, biosimilar, and interchangeable biosimilar products, FDA's December 2025 guidance addresses presenting data and information accurately, truthfully, and without misleading audiences (^[40]). Organizations using AI tools should maintain appropriate review and governance; the applicable obligations depend on the communication and regulatory context.

OPDP's Current Role: FDA describes the Office of Prescription Drug Promotion (OPDP) as continuing to review prescription-drug advertising and promotional labeling, initiate compliance letters for false or misleading promotional communications, and support policy-development initiatives, including guidance documents. Organizations should monitor current FDA publications and apply the requirements relevant to each promotional communication (^[41]).

Recent Guidance Documents: In December 2025, the FDA issued Promotional Labeling and Advertising Considerations for Prescription Biological Reference Products, Biosimilar Products, and Interchangeable Biosimilar Products: Questions and Answers. The guidance addresses promotional communications for those product categories and emphasizes that they should be accurate, truthful, and non-misleading (^[40]).

HIPAA and Privacy: HIPAA applies to covered entities and their business associates, and PHI includes individually identifiable health information held or transmitted by those parties. Where a remote session involves PHI in that context, organizations should apply the relevant Privacy and Security Rule requirements and use appropriate contractual and technical safeguards. Avoid assuming that a platform is categorically HIPAA-compliant; assess the particular deployment and applicable agreements (^[32]).

In short, the onus is on the pharma company to ensure remote calls meet all usual regulatory standards. Given 2025's enforcement activity and ongoing regulatory shifts, detailed record-keeping (call logs, content versions) and user permission controls are more critical than ever.

Key performance indicators (KPIs) should align with both commercial and technical goals. Useful ROI metrics include: number of remote calls per rep, HCP coverage rate, call duration/engagement, conversion to prescription or next-step, and cost per call (including savings on travel). On the revenue side, track sales lift or market share in territories with high remote interaction. On the cost side, measure reductions in travel expenses and printed materials.

Pharma CLM literature advises tracking sales growth and cost per conversion to assess ROI (^[42]). For example, if a remote detailing campaign costs $X, do sales of that product increase by more than $X? Reps can also log which accounts were reached virtually to ensure important HCPs aren't neglected. Other metrics from IT monitoring include platform uptime and call success rates (as service quality indicators). Feedback from HCPs (surveys or follow-up polls) can gauge satisfaction. In all cases, tying digital engagement data back to CRM (closed-loop marketing) is vital for measuring true impact (^[42]).

Remote detailing is now a permanent part of pharma's omnichannel mix. Industry experts agree face‑to‑face will remain important, but hybrid and AI-augmented strategies are the defining trend for 2026 and beyond. HTF Market Intelligence projects the e-detailing-for-pharma-reps market to reach $4.5 billion by 2033, with a stated forecast-period CAGR of 14.20%; the report separately lists year-on-year growth of 11.60% (^[43]).

2026: The Agentic Shift. In 2026, AI's role is poised to change dramatically—from delivering predictive insights to carrying out intelligent actions. This transformation, widely referred to as "the agentic shift," will see AI agents handle high-frequency, information-driven queries while human reps focus on strategic, relationship-driven conversations (^[44]). Available January 2026, a new integration between ZS and Salesforce extends Agentforce with life sciences-trained ZAIDYN agents delivering contextual recommendations and automating next-best actions.

AI Investment Surge: Menlo Ventures estimates that spending on healthcare-specific generative AI solutions reached $1.4 billion in 2025, nearly triple its 2024 estimate. Its estimate excludes general AI tools, non-LLM AI, and API spending, and therefore should not be treated as a pharmaceutical-AI market estimate (^[45]). Key AI-powered capabilities can include:

• Next-best-action engines that dynamically recommend which HCPs to target, when, via which channel, and with what content
• Voice-activated account preparation and podcast-style meeting recaps
• AI-powered content personalization adapting in real-time based on engagement patterns
• Compliance automation flagging potential regulatory issues before content is delivered

Platform Evolution: Platform capabilities and release timelines differ. Veeva announced that AI Agents for Vault CRM were planned to be available starting in December 2025 (^[26]). Salesforce offers Agentforce for Life Sciences within Life Sciences Cloud and stated that Podcast Stories, Agentforce Voice, and AI-enabled compliance were planned for February 2026; Regulated Content Management and Marketing Cloud Next integration were expected in late 2026 (^[28]). The cited material does not establish equivalent agentic-AI capabilities across every platform discussed.

Service-Oriented Engagement: Teams can design digital experiences to be useful resources rather than purely promotional touchpoints. Any use of agentic AI should be governed, reviewed, and evaluated for its effect on HCP engagement and compliance rather than assumed to improve attention or trust.

In summary, remote detailing has proven its value and is evolving rapidly with AI integration. IT teams that ensure secure, user-friendly deployments and integrate agentic AI capabilities will enable pharmaceutical companies to meet HCPs "on their terms" while dramatically improving engagement efficiency and compliance (^[8]) (^[46]).

Sources: Authoritative industry analyses, including IQVIA reports and surveys (^[47]) (^[7]) (^[8]), trade publications (^[48]) (^[49]), and official regulatory guidance, among others. These provide the data and insights summarized above.